Paul Robbins
Vice President, Clinical Translation Vividion Therapeutics
Translational scientist and drug developer experienced in all phases of development for small molecules, large molecules, biomarkers, diagnostics, cell and gene therapies for oncology, infectious disease and autoimmunity.
Seminars
Friday 19th March 2027
Panel Discussion: Translating the Multiple Myeloma Endpoint Precedent into Solid Tumor Programs to Shorten the Path to Regulatory Acceptance
12:00 pm
- Unpacking what secured MRD acceptance in myeloma and which elements transfer to solid tumors
- Addressing the sensitivity and heterogeneity challenges that make the solid tumor case fundamentally harder
- Sequencing the evidence generation so indications build on each other rather than starting from zero